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Regulation of anti-apoptotic signaling by Kruppel-like
factors 4 and 5 mediates lapatinib resistance in
breast cancer
MK Farrugia1,2, SB Sharma1,2, C-C Lin1,3, SL McLaughlin3, DB Vanderbilt1,2, AG Ammer3, MA Salkeni3,4, P Stoilov1,2,3, YM Agazie1,2,3,
CJ Creighton5 and JM Ruppert*,1,2,3
The Kruppel-like transcription factors (KLFs) 4 and 5 (KLF4/5) are coexpressed in mouse embryonic stem cells, where they
function redundantly to maintain pluripotency. In mammary carcinoma, KLF4/5 can each impact the malignant phenotype, but
potential linkages to drug resistance remain unclear. In primary human breast cancers, we observed a positive correlation between
KLF4/5 transcript abundance, particularly in the human epidermal growth factor receptor 2 (HER2)-enriched subtype. Furthermore,
KLF4/5 protein was rapidly upregulated in human breast cancer cells following treatment with the HER2/epidermal growth factor
receptor inhibitor, lapatinib. In addition, we observed a positive correlation between these factors in the primary tumors of
genetically engineered mouse models (GEMMs). In particular, the levels of both factors were enriched in the basal-like tumors of
the C3(1) TAg (SV40 large T antigen transgenic mice under control of the C3(1)/prostatein promoter) GEMM. Using tumor cells
derived from this model as well as human breast cancer cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing
cells to lapatinib. Indicating cooperativity, greater effects were observed when both genes were depleted. KLF4/5-deficient cells
had reduced basal mRNA and protein levels of the anti-apoptotic factors myeloid cell leukemia 1 (MCL1) and B-cell lymphoma-extra
large (BCL-XL). Moreover, MCL1 was upregulated by lapatinib in a KLF4/5-dependent manner, and enforced expression of MCL1 in
KLF4/5-deficient cells restored drug resistance. In addition, combined suppression of KLF4/5 in cultured tumor cells additively
inhibited anchorage-independent growth, resistance to anoikis and tumor formation in immunocompromised mice. Consistent
with their cooperative role in drug resistance and other malignant properties, KLF4/5 levels selectively stratified human HER2-
enriched breast cancer by distant metastasis-free survival. These results identify KLF4 and KLF5 as cooperating protumorigenic
factors and critical participants in resistance to lapatinib, furthering the rationale for combining anti-MCL1/BCL-XL inhibitors with
conventional HER2-targeted therapies.
Cell Death and Disease (2015) 6, e1699; doi:10.1038/cddis.2015.65; published online 19 March 2015
In mouse embryonic stem (ES) cells, pluripotency is main-
tained by the redundant function of three Kruppel-like
transcription factors, KLF2, KLF4 and KLF5.1 Furthermore,
as determined by chromatin immunoprecipitation combined
with high-throughput sequence analysis (ChIP-seq), KLF4
and KLF5 (KLF4/5) have both overlapping and distinct target
genes.2 Depletion of Klf4 or Klf5 in the anterior eye elicits
similar developmental phenotypes, whereas in other tissues
they exert opposing influences.3–5 For example, KLF4/5
differentially affect the expression of several cell cycle
regulatory proteins, such as CCND1, CCNB1 and
p21Waf1/Cip1.3 In adult tissues, KLF4 and/or KLF5 are induced
by a variety of stress stimuli and can promote cell survival in
diverse contexts.3,6–9
In breast cancer, KLF4/5 protein levels or mRNAabundance
are elevated in aggressive primary tumors.10–13 Consistent
with these results, promoter demethylation of KLF4 or KLF5 in
breast tumors is associated with an unfavorable clinical
course.14 Individually, both KLF4/5 exert oncogenic functions
in experimental models of cancer such as cellular transforma-
tion, migration, invasion and xenograft formation.15–19
Although signaling mechanisms remain to be elucidated,
KLF4 directly regulates the transcription of microRNA-206
(miR-206) to promote tumor cell survival and tumor initiation in
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athymic mice (manuscript submitted).18,20 Although indepen-
dently KLF4/5 have important roles in breast cancer, the
relationship between the two genes in this disease remains
understudied.
We observed a positive correlation of KLF4/5 expression in
the human epidermal growth factor receptor 2 (HER2)-
enriched breast cancer subtype. In addition, in these patients
the median expression of both KLF4/5 significantly stratified
the distant metastasis-free survival (DMFS). Clinically
approved HER2-targeted therapies such as lapatinib and
trastuzumab (Herceptin) have significantly improved the
disease-free survival (DFS) of patients with HER2-amplified
breast cancers.21,22 However, eventual resistance to these
therapies is observed in the majority of cases, representing a
major obstacle to long-term cures.23–26
Several mechanisms of resistance have been described,
often involving sustained signaling through dimerization with
other receptor tyrosine kinases (RTKs) or activatingmutations in
downstream effectors, namely RAS pathway components.27–32
Although numerous pathways to resistance have been char-
acterized, it is unclear which of these mechanisms predominate
in patients and how they are specifically regulated.
Interestingly, neutralization of apoptotic signaling contributes to
anti-HER2 therapeutic failure.33–35 For example, phosphorylation
of BAD or overexpression of B-cell lymphoma-extra large (BCL-
XL) reduces the efficacy of these drugs. One such drug is
lapatinib, a HER2/epidermal growth factor receptor (EGFR)
inhibitor that has activity not only in the HER2+ cancers of
patients, but also shows efficacy in combination with other agents
in basal-like breast cancermodels.36,37Weobserved that lapatinib
treatment of HER2-amplified tumor cells resulted in the rapid
induction of KLF4/5. Subsequent experiments demonstrated a
novel role for the endogenous KLFs in the regulation of anti-
apoptotic factors. As shown by shRNA studies, in the presence of
lapatinib KLF4/5 coregulated the expression of myeloid leukemia
cell 1 (MCL1) and cooperated to confer lapatinib resistance. Even
in the absence of drug treatment, the endogenous KLFs were
critical for maintaining basal levels of the anti-apoptotic factors
MCL1 and BCL-XL, and collaboratively promoted the malignant
phenotype. KLF4/5 were positively correlated with MCL1 in
primary breast tumors, and enforced expression of MCL1 was
sufficient to rescue the lapatinib sensitivity of KLF4/5-deficient
cells. These results identify KLF4/5 as inducible regulators of
lapatinib resistance through mediation of anti-apoptotic signaling.
Results
Klf4 and Klf5 are differentially expressed and positively
correlated in genetically engineered mouse models
(GEMMs) of breast cancer. To better understand how the
expression of these two KLFs are altered during mammary
tumorigenesis, we analyzed the levels of Klf4/5 in GEMMs of
breast cancer.38 As a complement to human tumor analysis,
individual GEMMs offer a genetically homogenous back-
ground where tumors arise in the context of specific genetic
alterations.
Of 108 tumors in the microarray data set, we analyzed 58
tumor samples across 9 different GEMMs.38 We omitted
models that had very low abundance of Klf4/5, including p53-
deficient models and models on the BALB/c background. We
also omitted samples that did not cluster into an intrinsic
subtype (14 tumor samples), and we excluded the mesench-
ymal subgroup tumors because of heterogeneity in GEMM
of origin (five tumors) (Figure 1a). Unlike for Klf5, Klf4
expression as determined by microarray analysis varied
substantially across the mouse model tumors, with higher
expression in mice transgenic for the coding region of SV40
large T antigen driven by the C3(1)/prostatein promoter
(i.e., C3(1) TAg) than in mouse mammary tumor virus
promoter (MMTV)-Neu tumors. Collectively, Klf4 levels were
significantly lower in GEMMs that generated predominantly
luminal tumors relative to tumors with basal characteristics
(Po0.0001).
Interestingly, the expression of Klf4/5 were positively
correlated in the 58 GEMM tumors (R=0.5658, Po0.0001;
Figure 1b, upper panel). Among the tumor subgroups, the
strongest correlation was observed in basal tumors
(R=0.8242, P=0.0005; Figure 1b, lower panel). Significant
correlations were also present in the luminal tumors (data not
shown). Indicating specificity, Klf4 or Klf5 did not correlate or
trend toward a correlation with another KLF, Klf2 (data not
shown).1
To more accurately quantitate gene expression, we isolated
spontaneous tumors from the C3(1) TAg and MMTV-Neu
models and measured mRNA levels by quantitative reverse
transcription and polymerase chain reaction (qRT-PCR;
Figure 1c, left panel). In the C3(1) TAg tumors, Klf4/5
abundance averaged 2.6- and 3.5-fold higher than normal
breast, respectively. In contrast, MMTV-Neu tumors showed
markedly reduced levels of both factors. The two models
differed in average abundance by 158- and 26-fold for Klf4/5,
respectively (Po0.0001). In these tumors, Klf4/5 mRNA
correlated strongly (Figure 1c, right panel; R= 0.8273,
P= 0.0024). Consistent with animal model data, the protein
expression of KLF4/5 in 10 different human breast cancer cell
lines was positively correlated (R= 0.8847, P= 0.0007;
Figure 1d). For KLF5, the smaller fragment of approximately
48 kDa present in the luminal breast cancer cell lines may be
attributed to estrogen-dependent processing.39
Figure 1 Klf4 and Klf5 are differentially expressed and positively correlated in GEMMs of breast cancer. (a) Microarray analysis of Klf4/5 levels across GEMMs of breast
cancer. Data for 58 mammary tumors from the Gene Expression Omnibus (GSE3165) were organized by GEMM and molecular subtype. Expression values were normalized to
whole mouse RNA (bars, S.D.). Klf4 levels in luminal and non-luminal tumors were compared via one-way ANOVA using Dunnet’s post test (Po0.0001). (b) Spearman’s
correlation was performed for the samples in panel a. (c) qRT-PCR analysis of total RNA isolated from tumors of MMTV-Neu or C3(1) TAg transgenic mice (left panel). Normal
mammary tissue from FVB/N mice was analyzed similarly (NL breast, N= 3). Tumor mean expression is depicted relative to the mean for normal tissue (bars, S.E.). The overall
mean tumor expression of Klf4 and Klf5 was compared between GEMMs using a two-tailed t-test (for each gene, Po0.0001). The log2 transformed data were assessed by
Spearman’s correlation (right panel). (d) Western blot analysis of KLF4/5 levels in whole-cell lysate of 10 different breast cancer cell lines. KLF expression was determined using
ImageJ and normalized to β-actin. The expression values were assessed by Spearman’s correlation (right panel)
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Prognostic significance of KLF4 and KLF5 in HER2-
enriched breast cancer. As KLF4/5 were correlated in
breast cancer models, we next examined whether this
relationship is informative to patient outcome. We performed
Kaplan–Meier analyses of DMFS using a previously
described compendium of gene expression profiling data
sets representing 1065 cases.40 Median expression levels
were used to define the groups. We excluded normal breast-
like tumors from analysis because these samples often
contain high amounts of contaminating normal cells.41
Across all tumors, KLF4 levels showed no signi-
ficant relationship with DMFS (Figure 2a). In contrast,
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elevated KLF5 was associated with shortened DMFS,
consistent with prior observations (hazard ratio (HR),
1.3; 95% confidence interval (CI), 1.1–1.7; P= 0.01;
Figure 2a).11
Interestingly, analysis of DMFS in each intrinsic subtype
revealed a trend for increased KLF5 expression and poor
outcome in the HER2-enriched tumors (HR, 1.6; CI, 1.0–2.5,
nominal P=0.05; Figure 2b). Furthermore, KLF4 expression
Figure 2 Prognostic significance of KLF4 and KLF5 in human breast cancer. Kaplan–Meier analysis utilized a previously described breast cancer microarray database.40
Red (hi) and blue (lo) groups were defined using the median gene expression level within the tumors of breast cancer patients. A total of 364 luminal A, 175 luminal B, 239 HER2-
enriched and 287 basal-like/claudin-low tumors were analyzed. (a) KLF4/5 were analyzed as single variables for all tumors combined. (b) KLF4/5 were analyzed as single
variables within the basal-like/claudin-low and the HER2-enriched groups, as defined by PAM50 subtyping. (c) The outcome of patients harboring tumors with higher expression
levels of both KLF4 and KLF5 (red, hi-hi) was compared with the outcome when tumors had lower expression levels of each factor (blue, lo-lo). For all curves, significance was
determined using the log-rank (Mantel–Cox) test and Po0.05 was considered significant
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showed a similar trend in this context (HR, 1.4; CI, 0.9–2.2,
P= 0.13). No such relationships were observed in a similarly
high-risk group, basal-like/claudin-low (Figure 2b), nor in the
luminal A or luminal B groups (Supplementary Figure 1).
Furthermore, the expression of KLF4/5 together (i.e.,
o median levels of each gene versus ≥ median levels
of each gene) considerably stratified DMFS in the HER2-
enriched subtype (HR, 2.4; CI, 1.2–4.5, P=0.011; Figure 2c).
HER2-enriched tumors with elevated KLF4/5 levels had
DMFS similar to 43% at 15 years post-diagnosis. This effect
was unique to the HER2-enriched subtype, as no other group
showed any trend (Figure 2c and Supplementary Figure 1). To
assess survival in patients with elevated expression of only
one of the two KLFs, we analyzed the four survival curves
defined by 2 × 2 contingency using the median scores for
KLF4/5 (Supplementary Figure 1). The log-rank test for trend
identified a significant trend between KLF4/5 expression and
median DMFS (P=0.016).
Endogenous KLF4/5 are induced by lapatinib in breast
cancer. We next examined the transcript abundance of
KLF4/5 as determined by RNAseq analysis of patient breast
tumors via The Cancer Genome Atlas (TCGA) Research
Network. Among the breast cancer intrinsic subtypes, we
observed the expression of the two factors to be most highly
correlated in HER2-enriched tumors (Figure 3a and
Supplementary Figure 2). Given that KLF4/5 appeared to
represent positively correlated prognostic factors in the
HER2-enriched breast cancer subtype, we subsequently
investigated the interdependence of KLF4/5 expression with
exposure to, or resistance to, HER2-targeted therapy.
Interestingly, lapatinib promoted the expression of both the
KLF4 and KLF5 proteins (Figure 3b). Trastuzumab treatment
yielded similar results (Figure 3c). In these experiments,
phosphorylated AKT levels served as a positive control for
HER2 inhibition (Figures 3b and c). These effects appeared to
be transcriptionally independent, as the respective mRNA
levels were not significantly altered (Figure 3d). Nor did
enhanced efficiency of protein translation appear to account
for upregulation of KLF4. Rather, the translational efficiency of
the full-length KLF4 transcript, as determined using a
previously described translation reporter, pMIR-Report-Luc-
KLF4-FL, was actually decreased by lapatinib treatment
(Figure 3e, left panel).18 This decrease is expected when
KLF4 transcriptional activity is elevated, attributed to a well-
characterized negative feedback signal by which KLF4
induces miR-206 and suppresses its own translation.18
Indeed, in lapatinib-treated cells the elevated KLF4 was
associated with increased levels of miR-206, which can then
directly target the KLF4 3’ UTR (Figure 3e, right panel).18,20
As neither KLF4 transcription nor its translational efficiency
appear to be upregulated by lapatinib, the results are
consistent with lapatinib-mediated stabilization of the KLF4
protein. Therefore, lapatinib may function similarly to serum
starvation to mediate a prolonged KLF4 half-life.42 Several
experiments to directly assess half-life were unsuccessful
because of the combined toxicity when cells were exposed to
both lapatinib and the protein synthesis inhibitor cyclohex-
imide. Nevertheless, the results indicate that lapatinib treat-
ment of HER2-positive breast cancer cells can enhance KLF4
protein expression and its transcriptional activity as indicated
by miR-206 levels.
Endogenous KLF4/5 mediate lapatinib resistance in
breast cancer. Based on these results, we hypothesized
that KLF4/5 are functionally important in the response to
lapatinib. We therefore depleted KLF4/5 in HER2-amplified
human BT474 and mouse M6 breast cancer cells, using
distinct shRNA hairpins for each of the human and mouse
genes (Figure 3f, left panels). M6 cells are a HER2-
overexpressing mammary cancer cell line derived from a
basal-like GEMM that is enriched for Klf4/5, the C3(1) TAg
model.43 Unlike many basal-like models, M6 cells over-
express both Egfr and Erbb2, the two RTKs targeted by
lapatinib. Compared with the nontargeting control, single
knockdown of KLF4 or KLF5 in the BT474 and M6 models
significantly sensitized the cells to lapatinib treatment
(Figure 3f, right panels). Moreover, coreduction of both
KLF4/5 further sensitized the cells to lapatinib, indicating
cooperativity. In these experiments, suppression of KLF5 led
to a subtle reduction of KLF4, suggesting the possibility of
crosstalk between the two factors (Figure 3f, left panels). In
agreement with the knockdown studies, ectopic expression of
KLF4/5 in M6 enhanced resistance to lapatinib treatment
(Figure 3g).
To further characterize their role in drug resistance, we
assessed mitochondrial membrane integrity (MMI) in these
cells following lapatinib exposure (Figure 3h). Disruption of
MMI is a key step of the intrinsic pathway of apoptosis.
Following 24 h of lapatinib treatment, the single knockdown
cell lines had reduced MMI compared with the controls and
suppression of both KLF4/5 produced an additive effect.
Supporting an impact of KLF4/5 on the intrinsic pathway of
apoptosis, reduction of KLF4/5 enhanced cleaved caspase-9
following exposure to lapatinib, with additive effects when both
KLFs were depleted (Figure 3i).
KLF4/5 cooperate to promote malignant properties. We
next determined whether KLF4/5 contributed to malignant
properties independently of lapatinib exposure. Relative to
the control, depletion of either KLF4 or KLF5 in M6 cells
significantly impacted anchorage-independent growth, as
indicated by reduced colony-forming ability (Figure 4a).
Furthermore, there was an additive reduction of colony
number following codepletion. We similarly observed coop-
erativity in a gain-of-function context, as ectopic expression of
KLF4/5 enhanced colony-forming ability in immortalized
human breast epithelial cells (HMLE, Figure 4b).
Expanding on this observation, we evaluated the ability of
these factors to impact tumor formation in athymic mice.
Individual reduction of each KLF significantly reduced
xenograft growth, with additive effects in the double knock-
down cells (Figure 4c, left panel). Comparable results on
tumor formation were obtained using an independent shRNA
to target each factor (Figure 4c, right panel).
To determine whether these results reflect deficiencies in
prosurvival signaling, we examined whether KLF4/5 could
cooperatively influence cell death following matrix deprivation
(anoikis). Single knockdown of KLF4 or KLF5 sensitized cells
to anoikis as determined by Trypan blue exclusion, with
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cooperative effects following codepletion (Figure 4d, left
panel). Conversely, overexpression of these factors in HMLE
enhanced anoikis resistance (Figure 4d, right panel). Deter-
mination of cell death by an independent method yielded
similar results (Figure 4e).
KLF4/5 depletion is associated with reduced expression
of anti-apoptotic B-cell lymphoma 2 (BCL2) family
members. As KLF4/5-depleted cells consistently exhibited
defects in cell survival, we analyzed molecular effectors of
this phenotype. The intrinsic pathway of apoptosis is critical in
both lapatinib resistance and anoikis.44 We therefore
examined the association of KLFs with factors known to
participate in apoptotic signaling.
In response to lapatinib or trastuzumab treatment, we
observed induction of not only KLF4/5 (Figures 3b and d), but
also the anti-apoptotic BCL2 members BCL2, BCL-XL
(BCL2L1) and MCL1 (Figure 5a). Although BCL2 was
increased in response to lapatinib, BCL2 levels were
decreased upon trastuzumab exposure, consistent with
previous studies.45 Despite the well-documented oncogenic
role for BCL2 in hematological malignancies, its expression is
correlates with a favorable patient outcome in breast cancer.46
Single knockdown of either KLF4 or KLF5 greatly reduced
BCL-XL levels in untreated M6 and BT474 cells (Figures 5b
and c, left panel). Interestingly, human KPL4 cells required
depletion of both KLFs to impact BCL-XL abundance, possibly
attributed to the activating phosphatidylinositide 3-kinase
(PI3K) mutation present in this HER2-amplified, inflammatory
breast cancer cell line (Figure 5b).47
In both BT474 and KPL4 cells, a reduction of the MCL1
protein level was evident when KLF4/5 were cosuppressed
(Figure 5b). Owing to lack of a suitable antibody, we could not
reliably detect murine MCL1 (Figure 5c, left panel). Regard-
less, in these cells the KLFs cooperated to maintain Mcl1 and
Bcl-xl transcript levels, as shown by qRT-PCR (Figure 5c, right
panel). Ectopic expression of KLF4/KLF5 in HMLE cells
cooperated to increase MCL1 expression, however, BCL-XL
levels responded primarily to KLF4 (Figure 5d).
Although the KLFs impacted BCL2 levels in M6 cells, this
regulation was not apparent in BT474 cells (Figures 5b and c).
qRT-PCR transcript analysis of other BCL2 family members
including Bad, Bax and Bid revealed no significant effects by
modulation of the two KLFs (data not shown).
To extend these in vitro studies, we assessed the
copresence of KLF4/5 expression with MCL1, BCL-XL and/or
BCL2 in human tumors (Table 1).48,49 Using a ± 1.5 z-score
range to define high and low expression groups, we evaluated
the mutual exclusivity/inclusivity in 958 human breast tumors
that were analyzed by microarray. Both KLF4/5 cooccurred
with MCL1. In addition, KLF4 and BCL-XL expression
levels were mutually inclusive, as were KLF5 and BCL2.
In agreement with our previous observations (Figure 3a),
KLF4/5 expression cooccurred in these tumors.
To more directly test for a correlation in patient samples, we
utilized the RNAseq database generated by TCGA. Across
890 breast tumors, the transcript abundance for KLF4, KLF5
and MCL1 was positively correlated (Figure 5e). Using this
data set, we observed no significant positive correlations
between KLFs and the other anti-apoptotic genes, BCL-XL
and BCL2 (data not shown). Despite these results, extensive
ChIP studies in BT474 cells that analyzed 5-kbp upstream of
the transcriptional start site, the body of the gene and 3-kbp
downstream, failed to identify any KLF4/5 association with the
mouse or human MCL1 loci (see Discussion section).
We next examined whether KLF4/5 expression was
required for the induction of anti-apoptotic molecules by
lapatinib. We focused on MCL1, as this molecule displayed a
robust induction following HER2 inhibition and exhibited
consistent relationships with the KLFs in human tumors
(Table 1,Figures 5a and e). To ensure a suitable number of
viable, lapatinib-sensitive KLF-depleted cells for analysis we
used a reduced lapatinib concentration of 250 nM. Although
individual reduction of KLF4 or KLF5 did not substantially
impact the lapatinib-mediated induction of MCL1 (data not
shown), cosuppression of both KLFs blunted this response
(Figure 5f).
To validate the importance of MCL1 in lapatinib resistance,
we reduced MCL1 levels in BT474 cells using siRNA smart
pool (Figure 5g). Compared with the nontargeting control,
siMCL1 cells demonstrated increased sensitivity to lapatinib
treatment. Similarly, a small molecule MCL1 inhibitor, UMI-77,
yielded comparable results to the siRNA studies (data not
shown). Conversely, MCL1 overexpression in KLF4/5 knock-
down BT474 cells was sufficient to restore lapatinib resistance
(Figure 5h).
Discussion
Targeted therapies have significantly improved the DFS of
breast cancer patients, including patients with ER+ or HER2+
breast cancers, and these therapies hold promise for triple-
Figure 3 Endogenous KLF4/5 mediate lapatinib resistance in breast cancer models. (a) Levels of KLF4/5 in primary human breast tumors were determined by RNAseq
(Illumina HiSeq RNAseqV2). Upper quartile normalized data were downloaded from TCGA and assigned a PAM50 subtype. Spearman’s correlation was performed on the log2
transformed data. (b) BT474 cells were treated with DMSO or lapatinib for the indicated interval. Whole-cell lysate was analyzed by western blot. Expression levels from three
independent experiments were determined using ImageJ for quantitation, with normalization to β-actin (bars, S.D.). (c) BT474 cells were treated with trastuzumab or sterile water
for the indicated interval and whole-cell lysate was analyzed by western blot. (d) KLF4/5 transcript levels were determined by qRT-PCR following lapatinib exposure. Expression
data were normalized using the housekeeping gene B2M. (e) The pMIR-Report-Luc-KLF4-FL translation reporter contains as an insert within the FLuc 3’ UTR the full-length
KLF4 transcript, including the KLF4 protein coding region and the flanking UTRs, as previously described.18 Translation efficiency was measured by determining normalized Fluc
activity in BT474 cells treated for 24 h with lapatinib or DMSO (left panel). miR-206 levels were determined by qRT-PCR following 24-h lapatinib exposure. Expression data were
normalized using U6 snRNA (right panel). (f) Cells were treated with the indicated shRNA construct, and the resulting cell populations were treated with lapatinib for 96 h. For each
cell population, cell viability relative to the DMSO control was obtained via ATP-based luminescence assay (bars, S.D.). (g) Similarly, the lapatinib effect on the relative cell viability
of M6 cells expressing ectopic KLF4 and/or KLF5 was determined. Empty vector served as a control. (h) To assess MMI, M6 cells were treated with lapatinib for 24 h, stained with
250 nM of Mitotracker dye and analyzed by flow cytometry. (i) To assess activity of the intrinsic apoptotic pathway, caspase-9 levels were determined in M6 cells expressing shCtl,
shKLF4, shKLF5 or shKLF4/5. Cells were treated with lapatinib for 24 h before preparation of cell extracts. *Po0.05; **Po0.01; ***Po0.001
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negative breast cancer (TNBC), particularly when used in
combination.36,37 For HER2+ breast cancer, clinically
approved therapies include the monoclonal antibodies trastu-
zumab and pertuzumab and, for third- or fourth-line therapy of
metastatic disease, the small molecule lapatinib.
For intrinsically aggressive breast cancers such as HER2-
enriched tumors, therapeutic resistance is common, as
evidenced by the progression of unresponsive tumors.23–26
Similar to lapatinib and trastuzumab, it is likely that resistance
mechanisms will impact the newer classes of HER2/EGFR
inhibitors, such as neratinib.50 Therefore, a better under-
standing of the molecular drivers of resistance could enable
the identification of effective drug combinations to improve
clinical efficacy.
Figure 4 KLF4/5 cooperate to promote malignant properties in M6 cells, a HER-2-overexpressing mammary cancer model. (a) Anchorage independence was assessed by
incubation of the indicated cell populations in soft agar for 14 days (N= 3, bars, S.E.). (b) Anchorage independence of HMLE cells expressing ectopic KLF4/5 was determined as
previously described. Empty vector (–) served as a control so that all cell populations were treated with equal volumes of lentiviral supernatant. (c) Cells were injected into the
mammary gland of female athymic mice and tumor xenograft volume was monitored over a period of several weeks (left panel, N= 5; bars, S.E.). Similar effects on tumor burden
were obtained using distinct shRNAs for the suppression of each KLF (right panel, N= 5; bars, S.E.). (d) Cell death was determined by Trypan blue exclusion following 24 h of
matrix deprivation for the indicated cell populations (N= 3; bars, S.E.). (e) As an independent method, cell death because of matrix deprivation in M6 cells was determined by
fluorescence microscopic imaging of DAPI/PI-stained cells. Results were quantitated using ImageJ (two-tailed t-test; N= 3; bars, S.E.). *Po0.05; **Po0.01; ***Po0.001
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Many studies support shared resistance mechanisms
between lapatinib and trastuzumab.27–32,35 These include
the sustained activation of downstream effectors of HER2
including PI3K, mTOR and mitogen-activated protein
kinase (MAPK). Through its regulation by these pathways or
by other signaling entities, the intrinsic cell death pathway
confers resistance to anti-HER2 treatments.33–35,45 Thus, the
therapeutic effect of anti-HER2 treatments can likely be
modulated using small molecule inhibitors or genetic
methods to perturb the balance between pro-apoptotic and
anti-apoptotic signaling. For example, a constitutively active
pro-apoptotic Bik enhances lapatinib-mediated apoptosis.33
Similarly, knockdown or overexpression of either MCL1, BCL2
or BCL-XL significantly alters the efficacy of lapatinib in
HER2-amplified cells.33,35
In our study, the KLFs mediated lapatinib resistance in a
cooperative manner, a result obtained in HER2-amplified
BT474 cells and in M6 cells, a HER2-overexpressing cell
line.38,51 Likely contributing to this effect, the two KLFs
independently impacted basal levels of the anti-apoptotic
factors MCL1 and BCL-XL in drug-naive cells. Furthermore, in
lapatinib-treated BT474 cells, we were surprised to observe
upregulation of BCL-XL and MCL1 upon HER2 inhibition. The
induction of MCL1 required the activity of KLF4/5, as indicated
Figure 5 KLF4/5 depletion is associated with reduced expression of anti-apoptotic BCL2 family members. (a) BT474 cells were treated with DMSO, 1 μM lapatinib, sterile
water or 10 μg/ml trastuzumab for the indicated time intervals. BCL2, BCL-XL and MCL1 levels were determined by western blot analysis. (b) Protein expression was analyzed in
control or KLF-depleted BT474 and KPL4 cells. (c) Protein expression (left panel) and mRNA expression (right panel) was analyzed in the indicated cell populations. (d) Protein
expression was analyzed in control HMLE cells and in cells expressing ectopic KLF4 and/or KLF5. (e) Spearman’s correlation between KLF4, KLF5 and MCL1 levels as
determined by RNAseq analysis of 890 human breast tumors. (f) The impact of KLF4/5 knockdown on the lapatinib-mediated induction of MCL1 was determined in BT474 cells.
Cells were treated with 250 nM lapatinib or DMSO for 24 h. For three independent experiments, the expression levels were quantitated using ImageJ and normalized to β-actin
(bars, S.D.). (g) MCL1 levels were reduced by siRNA and the resulting cell populations were treated with lapatinib for 96 h. For each cell population, cell viability relative to the
DMSO control was obtained via ATP-based luminescent assay (paired t-test, two tailed; bars, S.D.). (h) Similarly, lapatinib resistance was analyzed in KLF4/5 knockdown BT474
cells following rescue with exogenous MCL1 expression vector or empty vector control. *Po0.05; **Po0.01; ***Po0.001
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by analysis of the KLF4/5-deficient cells. We are currently
assessing other tumor models for KLF4/5-dependent upregu-
lation of anti-apoptotic factors in response to small molecule
inhibitors.
There are only a few established links between the KLFs,
anti-apoptotic BCL2 family proteins and HER2.52–54 In this
study, we observed coexpression of KLF4/5 and MCL1 in
human breast tumors and breast cancer models. Also, in
mouse ES cells the Mcl1 locus was significantly enriched via
ChIP-seq using antibodies to either KLF4 or KLF5.2,55 Despite
these results, and the clear dependence of MCL1 on KLF4/5
expression (Figures 5b and c), the MCL1 locus was not
enriched in KLF4/5 ChIP assays, in whichMIR206 served as a
positive control (data not shown).20 These results suggest an
indirect relationship, although the possibility of direct regula-
tion through a distal binding site cannot be excluded.
We found that KLF4/5 mRNA levels were correlated most
strongly in the HER2-enriched tumors, and these factors were
selectively prognostic within this subtype. Previous studies
have linked adverse clinical outcome to increased nuclear
localization of KLF4, to elevated KLF5 mRNA and to promoter
demethylation of KLF4 or KLF5.10–14 In our study, we observed
shortened DMFS for patients with HER2-enriched tumors
containing elevated levels of both KLF4 and KLF5, implicating
these two KLFs as novel prognostic factors (Figure 2d).
In any single breast tumor subtype or in all tumors
combined, KLF4 on its own had little effect (Figure 2b). In
contrast to these results, a previous study associated elevated
KLF4 transcript levels with prolonged DFS.56 As overall
survival, DFS and DMFS correlate strongly in breast cancer,
the utilization of these different endpoints seems unlikely to
account for the distinct results.57–59 Instead, the discrepancy
may be attributed to the analysis of different patient popula-
tions, to differences in sample size or to methodological
differences in sample processing.
This study identifies a novel drug resistance program
composed of KLF4/5, with likely origins in the stress response
signaling of KLFs in normal cells. In response to deficient RTK
signaling, KLF4/5 can coordinate a prosurvival response that
includes BCL2 family proteins, miR-206 and likely other
factors. Future studies will examine the predictive utility of
KLF4/5 for guiding patient therapy, for example, in patientswith
HER2+ tumors. Taken together, the identification of KLF4/5 as
intermediaries between HER2 and the BCL2 family members
significantly strengthens the rationale for combined therapeu-
tic inhibition of HER2 and BCL-XL/MCL1 to combat drug
resistance.
Materials and Methods
Cell lines and tissue culture. M6 cells were obtained from Jeffrey E Green
(National Cancer Institute, Bethesda, MD, USA), KPL4 cells were from Afsaneh
Keyhani (MD Anderson, Houston, TX, USA) and HMLE cells were from Robert A
Weinberg (Whitehead Institute, Cambridge, MA, USA). Cells were cultured as
previously described.51,60,61 T47D, BT-20, ZR-75-1, MCF7, HCC1937, BT474 and
HCC1143 cell lines were purchased from ATCC (Manassas, VA, USA) and cultured
in RPMI 1640. MDA-MB-453 cells were cultured in DMEM, whereas MDA-MB-361
and MDA-MB-468 were cultured in DMEM/Ham’s F12 50 : 50. All were
supplemented with 10% (v/v) FBS (Hyclone, GE Healthcare Life Sciences, Logan,
UT, USA), penicillin and streptomycin. Lapatinib (Selleck, Boston, MA, USA) was
dissolved in DMSO and used at the indicated concentrations. Trastuzumab
(Herceptin) was obtained from the Mary Babb Randolph Cancer Center
(Morgantown, WV, USA).
Transfections and retroviral transduction. The control shRNA vector
(nonsilencing-GIPZ lentiviral shRNA control (shCtrl); RHS4346) and the shRNA
vectors for murine Klf4 (V3LMM_459916, V3LMM_524009), murine Klf5
(V3LMM_489119, V2LMM_73715) and human KLF5 (V2LHS_150118 and
V2LHS_150120) were purchased from Open Biosystems (Pittsburgh, PA, USA).
shRNAs targeting human KLF4 have been previously described.20
siMCL1 ON-TARGETplus smart pool was purchased from Dharmacon (Lafayette,
CO, USA) and transfected using Lipofectamine RNAiMAX Reagent, Life Technologies
(Grand Island, NY, USA), as per the manufacturer’s recommendations.
Luciferase-based reporter assay of translational efficiency was performed as previously
reported, using pMIR-Report-Luc-KLF4-FL and with normalization to pRL-TK.18
KLF4/5 were expressed in human cells using the lentiviral vector, pLuT7. KLF4
was ectopically expressed in M6 cells using pBabe-puro-KLF4.18 pBabe-puro MCL1
was a gift from Roger Davis (Addgene, Cambridge, MA, USA; plasmid # 25371).62
Vectors were packaged into viral particles as previously described.18 Cells were
infected with viral supernatant supplemented with 10 μg/ml polybrene, centrifuged at
2500 r.p.m. for 1.5 h at 30 °C and selected in puromycin (1.0 μg/ml).
Immunoblot analysis. Cell lysis, gel electrophoresis, transfer and immunoblot
analysis was performed as described.18 Primary antibodies were KLF4 (H180,
Santa Cruz, Dallas, TX, USA), KLF5 (Millipore, Billerica, MA, USA), MCL1 (S19,
Santa Cruz), BCL-XL (L19, Santa Cruz), BCL2 (clone 7/Bcl-2, BD Biosciences, San
Jose, CA, USA), phospho-AKT(Ser473, Cell Signaling, Danvers, MA, USA), AKT
(Cell Signaling), Caspase-9 (Cell Signaling, 9502) and β-actin (C-4, Sigma,
St. Louis, MO, USA).
Animal studies. C3(1) TAg mice and MMTV-Neu mice (202Mul) were obtained
from Jax Labs (Bar Harbor, ME, USA). Female athymic nude mice (Charles River,
Frederick, MD, USA) were obtained at 6–8 weeks of age. In all, 2.0 × 106 cells were
injected into the fourth mammary fat pad in 100 μl of DMEM. Caliper measurements
were performed twice per week to measure tumor volume. Tumor volume was
calculated according to π(L1 × L22)/6 (L1, long axis; L2, short axis). All animal
procedures were performed under an approved ACUC protocol.
Quantitative, real-time, reverse transcription and PCR analysis
of mRNA. Mouse breast tumors or normal mammary glands were harvested
from killed mice and snap frozen. Tissue was mechanically dissociated using glass
beads and total RNA was isolated as previously described.63 For cell lines, total
RNA was extracted using the RNeasy minikit (Qiagen, Valencia, CA). qRT-PCR was
performed as previously described.18 Primers used for qRT-PCR can be found in
Supplementary Table 1. Of the housekeeping genes analyzed using RNA from
normal mouse mammary gland and tumors, including Rplp0, Gapdh and B2m, the
Rplp0 levels showed the best correlation with total RNA quantity. Gene expression
assays were therefore normalized using this transcript.64
Gene expression analysis of human breast tumors. Data generated
using the UNC Illumina HiSeq RNAseqV2 platform were downloaded from TCGA
(http://apps.nhlbi.nih.gov/grasp/, 11 March 2013). Statistical programming software
R (version 3.0.1) was used to assemble and process the data. Molecular subtyping
Table 1 The expression levels of KLF4/5 in breast cancer are mutually inclusive
with the anti-apoptotic BCL2 family members
Gene BCL-XL BCL2 MCL1 KLF5 KLF4
BCL-XL — 1.22E-1 1.59E-1 1.78E-1 1.00E-2a
BCL2 — 6.98E-4a 2.30E-5a 2.52E-1
MCL1 — 1.28E-2a 9.00E-6a
KLF5 — o1.00E-6a
KLF4 —
Using cBioPortal, the mutual inclusivity/exclusivity of KLF4/5 and anti-apoptotic
BCL2 family member expression was assessed in 958 human breast tumors
using a ± 1.5 z-score range. Transcript abundance was determined by
microarray. P-values were obtained by Fisher’s exact T-test (bold indicates
significance)
aDenotes an odds ratio (OR) range of 2–10. For this analysis, OR42.0 signifies
cooccurrence of expression within the tumor subsets as defined by the z-score
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was accomplished using the Bioconductor 2.12 genefu R package.65 At the time of
this study, patient follow-up data for TCGA samples were not sufficiently mature for
survival analysis. For survival analyses, the compendium of gene expression array
data sets of breast cancer was previously compiled, with subtypes assigned as
described elsewhere.40,66 Probes used for KLF4/5 were 221841_s_at and
209211_at, respectively.
Luminescence based cell viability assay. In all, 2 × 103 cells per
well (BT474) or 5 × 102 cells per well (M6) were transferred to 96-well plates and
cultured for 96 h in the indicated concentrations of lapatinib. Five replicates
were used for each concentration of drug. Fresh media and lapatinib was added to
the cells after 48 h. Viable cell number was determined via the ATPlite
Luminescence ATP Detection Assay System (PerkinElmer, Waltham, MA, USA).
Relative percent viability was determined by normalizing each condition to DMSO
treatment only.
Anoikis sensitivity assays. The anoikis procedure and quantitation of cell
death by Trypan blue exclusion was previously described.20 Alternatively, cell death
was determined using fluorescent microscopic analysis (Zeiss Axio Imager Z2,
Oberkochen, Germany) of cells stained with propidium iodide (PI) and 4',6-
diamidino-2-phenylindole (DAPI) to identify dead cells and total cell number,
respectively.67 Quantitation of PI/DAPI-stained cells was performed using Image J
(National Institutes of Health, Bethesda, MD, USA).
Soft agar colony formation. SeaPlaque agarose (Lonza, Anaheim, CA,
USA) was dissolved in 1X PBS and autoclaved. The agar layers contained complete
growth media and consisted of 1.0 ml 0.5% (w/v) agar underlay, 2.0 ml of 0.5% agar
cell layer containing 1.5 × 103 cells/ml and 1 ml of 0.3% agar overlay per well of a
six-well plate. In all, 250 μl of growth media was added onto the top layer. The
plates were wrapped in parafilm and incubated at 37 °C for 14 days, with an
additional 250 μl of complete growth media added after 7 days. Colonies were
visualized with a Perfection vV700 Photo scanner (Epson, Long Beach, CA, USA)
and colonies 4200 μm were counted.
Flow cytometry. Following 24- h treatment with 1 μM lapatinib, 5.0 × 105 M6
cells were washed twice with PBS, resuspended in 300 μl PBS containing 250 nM
Mitotracker Deep Red dye (Invitrogen/GE Healthcare, Logan, UT, USA), and
incubated at room temperature for 30 min. Stained cells were centrifuged at low
speed and then resuspended in PBS and analyzed in a BD FACS Calibur flow
cytometer (BD Biosciences) using BD CellQuest Pro software (BD Biosciences).
Plots were generated using FCS Express 4 (De novo software, Glendale, CA, USA).
Statistical analysis. Statistical analyses were performed in GraphPad Prism 6
(GraphPad Software, San Diego, CA, USA). RNA samples were independently
analyzed by qRT-PCR three times in duplicate manner (column, mean; bars, S.E.).
Correlations were obtained using Spearman’s correlation. Xenograft and drug
sensitivity assays were analyzed by repeated measures one-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparison post test. Other assays
including soft agar growth and anoikis were assessed by one-way ANOVA followed
by Tukey’s post test. Differences were considered significant when two-sided
analysis yielded P o 0.05.
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